Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment

(2019) Christian Rolfo et al.   CLINICAL PHARMACOKINETICS

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

(2018) Venkatesh Pilla Reddy et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

(2018) Michael Friedlander et al.   BRITISH JOURNAL OF CANCER

Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet formulations in Oncology Patients

(2018) Diansong Zhou et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

(2016) Luc Dirix et al.   CLINICAL THERAPEUTICS

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics

(2016) Sauzanne Khalilieh et al.   JOURNAL OF CLINICAL PHARMACOLOGY

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

(2016) J. Mateo et al.   Targeted Oncology

Pharmacokinetic drug interactions in liver disease: An update

(2016) Pietro Palatini   WORLD JOURNAL OF GASTROENTEROLOGY

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

(2015) Christian Rolfo et al.   ADVANCES IN THERAPY

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

(2015) Camille C Gunderson et al.   Future Oncology

The effects of mild or moderate hepatic impairment on the pharmacokinetics, safety, and tolerability of naloxegol

(2014) Khanh Bui et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance

(2010) Trevor N. Johnson et al.   CLINICAL PHARMACOKINETICS

405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments

(2010) J.E. Ang et al.   EJC SUPPLEMENTS